Form SC14D9C - Written communication relating to third party tender offer:
SEC Accession No. 0001193125-25-141503
Filing Date
2025-06-16
Accepted
2025-06-16 17:20:11
Documents
8

Document Format Files

Seq Description Document Type Size
1 SC14D9C d69141dsc14d9c.htm SC14D9C 20586
2 EX-99.2 d69141dex992.htm EX-99.2 144213
3 EX-99.3 d69141dex993.htm EX-99.3 1353
4 EX-99.4 d69141dex994.htm EX-99.4 14865
5 EX-99.5 d69141dex995.htm EX-99.5 68937
6 EX-99.6 d69141dex996.htm EX-99.6 6122
7 EX-99.7 d69141dex997.htm EX-99.7 14041
8 GRAPHIC g69141g50c02.jpg GRAPHIC 3893
  Complete submission text file 0001193125-25-141503.txt   277214
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filed by) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Subject) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C | Act: 34 | File No.: 005-88275 | Film No.: 251051133
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)